These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27164008)

  • 1. A novel therapeutic paradigm for patients with extensive alopecia areata.
    Renert-Yuval Y; Guttman-Yassky E
    Expert Opin Biol Ther; 2016 Aug; 16(8):1005-14. PubMed ID: 27164008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.
    Renert-Yuval Y; Guttman-Yassky E
    Adv Ther; 2017 Jul; 34(7):1594-1609. PubMed ID: 28646393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing.
    Suárez-Fariñas M; Ungar B; Noda S; Shroff A; Mansouri Y; Fuentes-Duculan J; Czernik A; Zheng X; Estrada YD; Xu H; Peng X; Shemer A; Krueger JG; Lebwohl MG; Guttman-Yassky E
    J Allergy Clin Immunol; 2015 Nov; 136(5):1277-87. PubMed ID: 26316095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases.
    Malik K; Guttman-Yassky E
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S62-S64. PubMed ID: 29273110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.
    Gilhar A; Schrum AG; Etzioni A; Waldmann H; Paus R
    Autoimmun Rev; 2016 Jul; 15(7):726-35. PubMed ID: 26971464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 inhibition: is it the long-awaited savior for alopecia areata?
    Ramot Y; Marzani B; Pinto D; Sorbellini E; Rinaldi F
    Arch Dermatol Res; 2018 Jul; 310(5):383-390. PubMed ID: 29497840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
    Trüeb RM; Dias MFRG
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations.
    Czarnowicki T; He HY; Wen HC; Hashim PW; Nia JK; Malik K; Estrada Y; Kimmel GW; Taliercio M; Krueger JG; Guttman-Yassky E
    Allergy; 2018 Mar; 73(3):713-723. PubMed ID: 29083474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational impact of omics studies in alopecia areata: recent advances and future perspectives.
    Basmanav FB; Betz RC
    Expert Rev Clin Immunol; 2022 Aug; 18(8):845-857. PubMed ID: 35770930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine pathways and interactions in alopecia areata.
    Giordano CN; Sinha AA
    Eur J Dermatol; 2013; 23(3):308-18. PubMed ID: 23797621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata.
    Ito T; Tokura Y
    Exp Dermatol; 2014 Nov; 23(11):787-91. PubMed ID: 25040075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The autoimmune basis of alopecia areata: a comprehensive review.
    Islam N; Leung PS; Huntley AC; Gershwin ME
    Autoimmun Rev; 2015 Feb; 14(2):81-9. PubMed ID: 25315746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alopecia areata in patients with inflammatory bowel disease: an overview.
    Sobolewska-Włodarczyk A; Włodarczyk M; Fichna J; Wiśniewska-Jarosińska M
    Folia Med Cracov; 2016; 56(1):5-12. PubMed ID: 27513834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata.
    Zhang X; Zhao Y; Ye Y; Li S; Qi S; Yang Y; Cao H; Yang J; Zhang X
    Arch Dermatol Res; 2015 May; 307(4):319-31. PubMed ID: 25638328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
    Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma-deficient mice are resistant to the development of alopecia areata.
    Freyschmidt-Paul P; McElwee KJ; Hoffmann R; Sundberg JP; Vitacolonna M; Kissling S; Zöller M
    Br J Dermatol; 2006 Sep; 155(3):515-21. PubMed ID: 16911275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata.
    Ito T; Kageyama R; Nakazawa S; Honda T
    Exp Dermatol; 2020 Aug; 29(8):726-732. PubMed ID: 32533873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast in Refractory Alopecia Areata.
    Estébanez A; Estébanez N; Martín JM; Montesinos E
    Int J Trichology; 2019; 11(5):213-215. PubMed ID: 31728104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab for alopecia areata treatment: A double-edged sword?
    Jin P; Wei L; Zhang Q; Gao T; Bai J; Dong L; Zhi L
    J Cosmet Dermatol; 2022 Nov; 21(11):5546-5548. PubMed ID: 35652739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alopecia areata and the gut-the link opens up for novel therapeutic interventions.
    Borde A; Åstrand A
    Expert Opin Ther Targets; 2018 Jun; 22(6):503-511. PubMed ID: 29808708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.